IXICO plc New contract to support Phase II clinical trial (6071S)
October 04 2017 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 6071S
IXICO plc
04 October 2017
4 October 2017
IXICO plc
("IXICO" or the "Company")
IXICO signs new contract to deploy biosensors in a Phase II
neurological clinical trial
First commercial contract using IXICO's wearable biosensor
technology
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, today announces that it has signed a new contract,
with a top 15 global pharmaceutical company, utilising wrist worn
activity sensors ('wearable biosensors') in a Phase II clinical
trial for a neurological disorder.
This is IXICO's first commercial agreement using activity
sensors to evaluate exploratory digital measures in early phase
clinical research and follows a presentation of IXICO's approach to
measuring sleep disturbances at the "Mobile devices for clinical
trials in neurological diseases workshop" earlier this year at the
Clinical Data Interchange Standards Consortium (CDISC) and the
Critical Path Institute Coalition Against Major Diseases (CAMD)
meetings.
This contract has a value of around GBP0.5m over a two year
term, commencing in September 2017. IXICO will utilise its
biosensor clinical trial capabilities, combined with its artificial
intelligence data analytics algorithms, to measure activity and
sleep disturbances from biosensor data collected from c.300
people.
Sleep disturbance is a challenging symptom of many brain
diseases including Parkinson's and Alzheimer's Disease and is also
a side effect of many drug treatments. The work performed in this
clinical trial, represents an important step in the validation of
biosensors as new digital technologies in a specific context of
use, as required by regulatory authorities.
Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be
deploying wearable biosensors and our proprietary algorithms to
measure sleep disturbance in a commercial clinical trial. This is
an excellent opportunity for IXICO to demonstrate how our biosensor
services and technology, build upon our well-established expertise
in providing regulatory compliant imaging endpoints in clinical
trials, to support the process of developing new drugs to treat
neurological diseases."
For further information please contact:
IXICO plc Tel: +44 20 3763
Giulio Cerroni, Chief Executive 7499
Officer
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield /James 7408 4090
Wolfe
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTBUBDGXSGBGRX
(END) Dow Jones Newswires
October 04, 2017 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024